ClinicalTrials.gg
RecruitingNCT06976216MINDSET 1Updated Oct 27, 2026

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

A Phase 3 interventional study of KarXT and KarX-EC in Alzheimer's Disease, sponsored by Bristol-Myers Squibb. Recruiting at 119 sites in 19 countries. Open to participants aged 60 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Oct 27, 20265 sites added5 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
586
Allocation
Randomized
Ages
60 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing xanomeline in Alzheimer Disease — 10 open to participants now, 10 under way, 10 of them phase 3. xanomeline · Alzheimer Disease.

Planned enrollment
3rd of 10
586 · median 463
Started
2025
with 4 others
Phase 3
10 of 10
10 open now
Registered
7th of 10
by date
Lead sponsor
6 of 10
Bristol-Myers Squibb

Among the 10 studies testing xanomeline in Alzheimer Disease, this one is the 3rd largest by planned enrollment, is one of 5 that started in 2025, is one of 10 in phase 3, and was the 7th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

10 of the 10 studies testing xanomeline in Alzheimer Disease are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About xanomeline

xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 60 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing xanomeline in Alzheimer Disease, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease

03

Conditions studied

  • Alzheimer's Disease

Keywords

  • Dementia
  • Cognitive Impairment
  • Kar-XT
  • KarX-EC
  • Mild Alzheimer's Disease
  • Moderate Alzheimer's Disease
04

Who can participate

Ages eligible
60 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a confirmed diagnosis of Alzheimer's disease (AD), specifically at the mild (stage 4) or moderate (stage 5) dementia stages, as defined by the National Institute on Aging and Alzheimer's Association (NIA-AA) core clinical criteria. The diagnosis of AD pathology must be confirmed through the 2024 revised NIA-AA Workgroup criteria using a stepwise diagnostic approach.
  • Participants must have an (MMSE) score ranging from 12 through 22, inclusive, at the time of screening.
  • Participants must have a designated caregiver who maintains adequate contact (around 10 hours per week or more) and is willing to attend all study visits. The caregiver must also be responsible for reporting on the participant's condition, overseeing medication compliance, and consenting to their involvement in both their own and the participant's study-related activities.
  • Participants on acetyl choline esterase inhibitors (AChEIs) and/or memantine, must have been on a stable dosage for at least 12 weeks prior to screening, and agree to maintain this stable dose for the study duration.

Exclusion criteria

Exclusion Criteria

  • Participants must not present with any significant or severe medical conditions that could compromise their safety, the ability to comply with or complete the study, or the integrity of the study results. This includes any grade of hepatic impairment, urinary retention, active biliary disease, moderate-severe renal impairment ( of \<50 mL/min), and unstable hypertension or tachycardia.
  • Participants must not have any primary psychiatric diagnoses such as major depression, schizoaffective disorder, or bipolar disorder, and those with severe psychiatric symptoms that could complicate the interpretation of treatment effects, impair cognitive assessment, or impact study completion.
  • Participants must not have a history of schizophrenia or other chronic psychosis, as well as those who have previously been exposed to KarXT or are currently undergoing treatment with disease-modifying anti-amyloid therapies for AD within the past 6 months prior to screening.
  • Participants must not have significant pathological findings on brain magnetic resonance imaging (MRI) at screening that reflect significant pathology other than AD or could affect safety or interfere with study procedures.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
586 participants (estimated)

Study arms

  • Active comparator
    KarXT + KarX-EC

    Drug: KarXT · Drug: KarX-EC

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • DrugKarXT

    Drug pages: Xanomeline · Trospium

    Specified dose on specified days

    Also known as: BMS-986510

  • Specified dose on specified days

    Also known as: BMS-986519

  • OtherPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11)

    Time frame: At week 24

  2. Clinician's Interview-Based Impression Plus Caregiver Input (CIBIC+)

    Time frame: At week 24

Secondary outcomes

  1. Change from baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL)

    Time frame: At week 24

  2. Change from baseline in neuro psychiatric inventory (NPI) total score

    Time frame: At week 24

  3. Number of participants with adverse events (AEs)

    Time frame: At week 24

  4. Number of participants with serious adverse events (SAEs)

    Time frame: At week 24

  5. Number of participants with adverse event of special interest (AESIs)

    Time frame: At week 24

  6. Number of participants with AEs leading to study intervention discontinuation

    Time frame: At week 24

  7. Number of participants with AEs leading to study discontinuation

    Time frame: At week 24

  8. Number of participants with AEs leading to death

    Time frame: At week 24

  9. Number of participants with clinically significant changes in vital signs

    Time frame: At week 24

  10. Number of participants with clinically significant changes in electrocardiogram (ECG) tests

    Time frame: At week 24

  11. Number of participants with clinically significant changes in Columbia-Suicide Severity Rating Scale (C-SSRS) tests

    Time frame: At week 24

  12. Number of participants with clinically significant changes in weight

    Time frame: At week 24

  13. Number of participants with clinically significant changes in safety laboratory tests

    Time frame: At week 24

07

Study locations

89 of 119 sites recruiting
  • Healthy Brain Clinic
    Long Beach, California 90804, United States
    Recruiting
    • Dung Trinh, Site 0173 · Contact562-606-5999
  • Anderson Clinical Research
    Redlands, California 92374, United States
    Recruiting
    • Donald Anderson, Site 0008 · Contact909-792-9007
  • Mountain Neurological Research Center
    Basalt, Colorado 81621, United States
    Recruiting
    • Alison Allen, Site 0025 · Contact970-927-1141
  • Georgetown University Medical Center
    Washington D.C., District of Columbia 20007, United States
    Recruiting
    • Raymond Turner, Site 0024 · Contact202-687-7337
  • JEM Research Institute
    Atlantis, Florida 33462, United States
    Recruiting
    • Linda Pao, Site 0154 · Contact561-968-2933
  • VIN-Julie Schwartzbard
    Aventura, Florida 33180, United States
    Recruiting
    • Julie Schwartzbard, Site 0128 · Contact833-732-2484
  • Merritt Island Medical Research, LLC
    Merritt Island, Florida 32952, United States
    Recruiting
    • Wasim Niazi, Site 0023 · Contact386-785-8009
  • Renstar Medical Research
    Ocala, Florida 34470, United States
    Recruiting
    • Anette Nieves, Site 0055 · Contact352-629-5800
  • Alzheimer's Research and Treatment Center
    Stuart, Florida 34996, United States
    Recruiting
    • Adam Falchook, Site 0263 · Contact561-209-2400
  • Charter Research - Lady Lake
    The Villages, Florida 32162, United States
    Recruiting
    • Jeffrey Norton, Site 0184 · Contact352-775-1000
  • Local Institution - 0016
    Columbus, Georgia 31909, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Center for Advanced Research & Education
    Gainesville, Georgia 30501, United States
    Recruiting
    • Angela Ritter, Site 0125 · Contact770-519-5254
  • Re:Cognition Health - Chicago
    Chicago, Illinois 60611, United States
    Recruiting
    • Antonio Iglesias, Site 0109 · Contact312-971-3318
  • Ascension Alexian Brothers
    Elk Grove Village, Illinois 60007, United States
    Recruiting
    • Concetta Forchetti, Site 0054 · Contact847-593-8553
  • Boston Center for Memory
    Newton, Massachusetts 02459, United States
    Recruiting
    • Paul Solomon, Site 0009 · Contact413-281-0577
  • HealthPartners Neuroscience Center
    Saint Paul, Minnesota 55130, United States
    Recruiting
    • Marcel Hungs, Site 0110 · Contact111-111-1111
  • Advanced Memory Research Institute of New Jersey
    Toms River, New Jersey 08755, United States
    Recruiting
    • Arun Singh, Site 0123 · Contact732-341-9500
  • NYU Langone Health
    New York, New York 10016, United States
    Recruiting
    • Martin Sadowski, Site 0101 · Contact212-263-5708
  • Local Institution - 0259
    New York, New York 10029, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
    Recruiting
    • Andrea Berg, Site 0202 · Contact
  • Local Institution - 0007
    Matthews, North Carolina 28105, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Ohio State University
    Columbus, Ohio 43221, United States
    Recruiting
    • Douglas Scharre, Site 0073 · Contact
  • NDx Clinical Research Inc.
    Dayton, Ohio 45459, United States
    Recruiting
    • Joel Vandersluis, Site 0026 · Contact305-456-7782
  • Summit Headlands
    Portland, Oregon 97210, United States
    Recruiting
    • Scott Losk, Site 0067 · Contact503-279-8252
  • Local Institution - 0004
    Abington, Pennsylvania 19001, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Rhode Island Mood & Memory Research Institute
    East Providence, Rhode Island 02914, United States
    Recruiting
    • john stoukides, Site 0056 · Contact401-435-8950
  • Neurology Clinic, P.C.
    Cordova, Tennessee 38018, United States
    Recruiting
    • Thomas Arnold, Site 0099 · Contact901-866-9252
  • Gadolin Research
    Beaumont, Texas 77702, United States
    Recruiting
    • Joseph Oommen, Site 0018 · Contact409-331-6040
  • Fundación para el Estudio y Tratamiento de Enfermedades Mentales (FETEM)
    Buenos Aires, Buenos Aires F.D. 1133, Argentina
    Recruiting
    • Ricardo Corral, Site 0001 · Contact5491144455572
  • Local Institution - 0271
    Buenos Aires, 1280, Argentina
    Not yet recruiting
    • Site 0271 · Contact
  • Fundación Lennox - Instituto Modelo de Neurología
    Córdoba, 5000, Argentina
    Recruiting
    • Georgina Viczena, Site 0232 · Contact+5493515993881
  • Sanatorio Morra S.A.
    Córdoba, 5000, Argentina
    Recruiting
    • Carlos Morra, Site 0228 · Contact+543514822191
  • Instituto Kremer
    Córdoba, X5004AOA, Argentina
    Recruiting
    • Leonardo Kremer, Site 0085 · Contact543515000000
  • Southern Neurology
    Kogarah, New South Wales 2217, Australia
    Recruiting
    • Colin Mahoney, Site 0279 · Contact+61 2 8566 1500
  • KARA Institute for Neurological Diseases
    Macquarie Park, New South Wales 2113, Australia
    Recruiting
    • Kathryn Goozee, Site 0245 · Contact61 2 8960 7788
  • NeuroCentrix
    Carlton, Victoria 3053, Australia
    Recruiting
    • David Barton, Site 0242 · Contact+61 3 9546 0009
  • Neurodegenerative Disorders Research
    Perth, Western Australia 6005, Australia
    Recruiting
    • Peter Panegyres, Site 0243 · Contact+61 8 6317 9472
  • St Vincent's Hospital Sydney Limited
    Darlinghurst, 2010, Australia
    Recruiting
    • Bruce Brew, Site 0244 · Contact61 2 8382 4983
  • L2IP - Instituto de Pesquisas Clínicas
    Brasília, Federal District 70200730, Brazil
    Recruiting
    • Eduardo Vasconcellos, Site 0168 · Contact55-6199983-1080
  • Instituto de Neurologia de Curitiba
    Curitiba, Paraná 81210310, Brazil
    Recruiting
    • Pedro Kowacs, Site 0180 · Contact+5541999775432
  • Local Institution - 0266
    Aracaju, Sergipe 49075-000, Brazil
    Not yet recruiting
    • Site 0266 · Contact
  • Hospital das Clinicas FMUSP
    São Paulo, 05403-000, Brazil
    Recruiting
    • Sonia Brucki, Site 0165 · Contact+5511996466593
  • OCT Research ULC
    Kelowna, British Columbia V1Y 1Z9, Canada
    Recruiting
    • Pieter Strauss, Site 0233 · Contact250-862-8141
  • Richmond Clinical Trials
    Richmond, British Columbia V6V 2L1, Canada
    Recruiting
    • Harris Lari, Site 0234 · Contact604-373-4954
  • Centricity Research Halifax Multispecialty
    Halifax, Nova Scotia B3S 1N2, Canada
    Recruiting
    • Kerrie Schoffer, Site 0236 · Contact902-609-6845 x7115
  • Ottawa Memory Clinic
    Ottawa, Ontario K1Z 1G3, Canada
    Recruiting
    • Richard Bergeron, Site 0237 · Contact1-613-702-1000
  • Toronto Memory Program
    Toronto, Ontario M3B 2S7, Canada
    Recruiting
    • Manpreet Kaur, Site 0235 · Contact416-386-9606
  • MoCA Research and Innovation Inc.
    Greenfield Park, Quebec J4V 2J2, Canada
    Recruiting
    • Ziad Nasreddine, Site 0238 · Contact450-672-7766
  • Diex Recherche Victoriaville
    Victoriaville, Quebec G6P 3Z8, Canada
    Recruiting
    • Ethel Bellavance, Site 0239 · Contact819-260-1172
  • ALPHA Recherche Clinique
    Québec, G3K 2P8, Canada
    Recruiting
    • Claude Patry, Site 0264 · Contact418-847-1112
  • Local Institution - 0094
    Santiago, Santiago Metropolitan 7500710, Chile
    Not yet recruiting
    • Site 0094 · Contact
  • Especialidades Médicas LYS
    Santiago, Santiago Metropolitan 7560356, Chile
    Recruiting
    • Manuel Lavados, Site 0089 · Contact222016979
  • Local Institution - 0241
    Santiago, Santiago Metropolitan 8380420, Chile
    Not yet recruiting
    • Site 0241 · Contact
  • Local Institution - 0230
    Antofagasta, 1270244, Chile
    Not yet recruiting
    • Site 0230 · Contact
  • Local Institution - 0215
    Zagreb, City of Zagreb 10000, Croatia
    Not yet recruiting
    • Site 0215 · Contact
  • Poliklinika Neuron
    Zagreb, City of Zagreb 10000, Croatia
    Recruiting
    • Neven Henigsberg, Site 0284 · Contact+38514596866
  • Klinika za psihijatriju "Vrapče"
    Zagreb, 10090, Croatia
    Recruiting
    • Ninoslav Mimica, Site 0240 · Contact+38513780678
  • Neuro Health Centrum
    Brno, Brno-město 628 00, Czechia
    Recruiting
    • Katerina Sheardova, Site 0227 · Contact+420603198029
  • AGE Centrum
    Olomouc, Olomouc Region 779 00, Czechia
    Recruiting
    • Dagmar Malotova, Site 0225 · Contact00420723060809
  • A-Shine
    Pilsen, Plzeň-město 301 00, Czechia
    Recruiting
    • Lubos Janu, Site 0221 · Contact420777242101
  • Neurologická Ambulance - Forbeli
    Prague, Praha 6 160 00, Czechia
    Recruiting
    • Michal Bajacek, Site 0224 · Contact+420608164394
  • Neuropsychiatrie
    Prague, Praha 6 160 00, Czechia
    Recruiting
    • Jakub Hort, Site 0223 · Contact+420224434700
  • Institut neuropsychiatricke pece (INEP), Praha
    Prague, Praha 8 18600, Czechia
    Recruiting
    • Alexander Nawka, Site 0222 · Contact+420605809745
  • Vestra Clinics
    Rychnov nad Kněžnou, 516 01, Czechia
    Recruiting
    • Ladislav Pazdera, Site 0226 · Contact420604236033
  • Local Institution - 0295
    Nice, Alpes-Maritimes 06100, France
    Not yet recruiting
    • Site 0295 · Contact
  • Local Institution - 0289
    Toulouse, Haute-Garonne 31000, France
    Not yet recruiting
    • Site 0289 · Contact
  • Local Institution - 0290
    Rouen, Haute-Normandie 76031, France
    Not yet recruiting
    • Site 0290 · Contact
  • Local Institution - 0291
    Montpellier, Languedoc-Roussillon 34295, France
    Not yet recruiting
    • Site 0291 · Contact
  • Local Institution - 0299
    Reims, Marne 51092, France
    Not yet recruiting
    • Site 0299 · Contact
  • Local Institution - 0293
    Villeurbanne, Rhône 69100, France
    Not yet recruiting
    • Site 0293 · Contact
  • Local Institution - 0294
    Dijon, 21079, France
    Not yet recruiting
    • Site 0294 · Contact
  • Local Institution - 0301
    Mannheim, Baden-Wurttemberg 68159, Germany
    Not yet recruiting
    • Site 0301 · Contact
  • Universitätsklinikum Münster - Albert Schweitzer Campus
    Münster, North Rhine-Westphalia 48149, Germany
    Recruiting
    • Matthias Pawlowski, Site 0219 · Contact+492518348239
  • Universitätsmedizin Johannes Gutenberg Universität Mainz
    Mainz, Rhineland-Palatinate 55131, Germany
    Recruiting
    • Susanne Englisch, Site 0276 · Contact+49613117-2920
  • Charite-Universitaetsmedizin Berlin - Campus Benjamin Franklin (CBF)
    Berlin, State of Berlin 12203, Germany
    Recruiting
    • Julian Hellmann-Regen, Site 0218 · Contact+4930450517654
  • Local Institution - 0300
    Aachen, 52074, Germany
    Not yet recruiting
    • Site 0300 · Contact
  • Local Institution - 0302
    Berlin, 12203, Germany
    Not yet recruiting
    • Site 0302 · Contact
  • Local Institution - 0277
    Bremen, 28325, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0275
    Hamburg, 20246, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • TUM Klinikum
    Munich, 81675, Germany
    Recruiting
    • Timo Grimmer, Site 0217 · Contact+498941404262
  • University General Hospital of Alexandroupoli
    Alexandroupoli, Anatolikí Makedonía Kai Thráki 681 00, Greece
    Recruiting
    • KONSTANTINOS VADIKOLIAS, Site 0281 · Contact+302551030351
  • Local Institution - 0256
    Athens, Attikí 115 25, Greece
    Withdrawn

    Not enrolling at this site — choose another above.

  • Aiginiteio University Hospital
    Athens, Attikí 115 28, Greece
    Recruiting
    • Nikolaos Scarmeas, Site 0274 · Contact
  • University General Hospital of Larissa
    Larissa, Thessalía 41110, Greece
    Recruiting
    • Efthimios Dardiotis, Site 0257 · Contact00306974224279
  • Local Institution - 0288
    Bengaluru, Karnataka 560029, India
    Not yet recruiting
    • Site 0288 · Contact
  • Local Institution - 0282
    Hyderabad, Telangana 500034, India
    Not yet recruiting
    • Site 0282 · Contact
  • Local Institution - 0285
    Hyderabad, Telangana 500082, India
    Not yet recruiting
    • Site 0285 · Contact
  • Local Institution - 0287
    Varanasi, Uttar Pradesh 221005, India
    Not yet recruiting
    • Site 0287 · Contact
  • Local Institution - 0286
    Kolkata, West Bengal 700054, India
    Not yet recruiting
    • Site 0286 · Contact
  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
    Milan, Lombardy 20122, Italy
    Recruiting
    • Andrea Arighi, Site 0249 · Contact+390255033842
  • Ospedale San Raffaele
    Milan, Lombardy 20132, Italy
    Recruiting
    • Massimo Filippi, Site 0246 · Contact+390226433958
  • Fondazione IRCCS San Gerardo dei Tintori
    Monza, Lombardy 20900, Italy
    Recruiting
    • Fulvio Da Re, Site 0248 · Contact0392332440
  • Azienda Ospedaliera Spedali Civili di Brescia
    Brescia, 25123, Italy
    Recruiting
    • Salvatore Caratozzolo, Site 0247 · Contact+393930406304
  • Brain Research Center Den Bosch B.V.
    's-Hertogenbosch, North Brabant 5223 LA, Netherlands
    Recruiting
    • Paul Dautzenberg, Site 0296 · Contact+31736996000
  • Local Institution - 0297
    Amsterdam, North Holland 1081 GN, Netherlands
    Not yet recruiting
    • Site 0297 · Contact
  • Local Institution - 0298
    Zwolle, Overijssel 8025 AZ, Netherlands
    Not yet recruiting
    • Site 0298 · Contact
  • Centrum Medyczne HCP
    Poznan, Greater Poland Voivodeship 61-485, Poland
    Recruiting
    • Przemyslaw Osip, Site 0262 · Contact+48604116632
  • Osrodek Badan Klinicznych CLINSANTE S.C.
    Torun, Kuyavian-Pomeranian Voivodeship 87-100, Poland
    Recruiting
    • Marzena Maryniak-Wisniewska, Site 0261 · Contact+48601638933
  • MlynowaMed Psychiatric
    Bialystok, Podlaskie Voivodeship 15-404, Poland
    Recruiting
    • Joanna Lazarczyk, Site 0280 · Contact0048792009929
  • Penta Hospitals Badania Kliniczne - Gdańsk 1
    Gdansk, Pomeranian Voivodeship 80-546, Poland
    Recruiting
    • Katarzyna Binkowska-Michalik, Site 0260 · Contact+48587192222

Showing the first 100 of 119 sites across 19 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Sep 2028, 37 months after the start.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's planned 37 months is below that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2025
First posted
May 16, 2025
StartActual
Jul 14, 2025
Primary completionEst.
Sep 11, 2028
CompletionEst.
Feb 23, 2029
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 5 sites removed
Show 5 added (1 United States, 1 Brazil, 1 Chile, 1 Czechia, 1 Netherlands)
  • Local Institution - 0007 · Matthews, United States
  • L2IP - Instituto de Pesquisas Clínicas · Brasília, Brazil
  • Especialidades Médicas LYS · Santiago, Chile
  • Institut neuropsychiatricke pece (INEP), Praha · Prague, Czechia
  • Brain Research Center Den Bosch B.V. · 's-Hertogenbosch, Netherlands
Show 5 removed
  • AMC Research, LLC · Matthews, United States
  • Local Institution - 0168 · Brasília, Brazil
  • Local Institution - 0089 · Santiago, Chile
  • Local Institution - 0222 · Prague, Czechia
  • Local Institution - 0296 · 's-Hertogenbosch, Netherlands
across 2 updates, Oct 6, 2026 – Oct 27, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • NDx Clinical Research Inc. · Dayton, United StatesContact •••8200→•••7782
Oct 6, 2026
Show all 2 updates
  1. Oct 27, 2026
    1 site added, 1 site removed
    Show site
    • Brain Research Center Den Bosch B.V. · 's-Hertogenbosch, Netherlands
    Show 1 removed
    • Local Institution - 0296 · 's-Hertogenbosch, Netherlands
  2. Oct 6, 2026
    4 sites added, 4 sites removed
    Show 4 added (1 United States, 1 Brazil, 1 Chile, 1 Czechia)
    • Local Institution - 0007 · Matthews, United States
    • L2IP - Instituto de Pesquisas Clínicas · Brasília, Brazil
    • Especialidades Médicas LYS · Santiago, Chile
    • Institut neuropsychiatricke pece (INEP), Praha · Prague, Czechia
    Show 4 removed
    • AMC Research, LLC · Matthews, United States
    • Local Institution - 0168 · Brasília, Brazil
    • Local Institution - 0089 · Santiago, Chile
    • Local Institution - 0222 · Prague, Czechia
    Site contacts Changed at 1 site. See the sites
    Show the site
    • NDx Clinical Research Inc. · Dayton, United StatesContact •••8200→•••7782
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06976216
Responsible party
Sponsor
First posted
May 16, 2025
Start date
Jul 14, 2025
Primary completion
Sep 11, 2028 (estimated)
Completion
Feb 23, 2029 (estimated)
Last update
Oct 27, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xanomeline · Trospium

Start the discussion